How should I taper a patient off intravenous morphine?

How to Taper Intravenous Morphine

Taper morphine slowly at 10% per month or slower for patients who have received it for extended periods (≥1 year), with faster tapers of 10% per week acceptable for shorter-term use, while actively monitoring and treating withdrawal symptoms with adjuvant medications. 1, 2

Core Tapering Principles

Never Abruptly Discontinue

• The FDA explicitly warns against abrupt discontinuation of morphine, which can precipitate severe withdrawal symptoms including restlessness, anxiety, insomnia, abdominal cramps, diarrhea, tachycardia, hypertension, and mydriasis 3
• Abrupt discontinuation has been associated with mental health crises, overdose events, and overdose death 1

Taper Rate Selection Based on Duration of Use

For short-term use (days to weeks):

• Start with 10% reductions per week 2
• Can proceed more rapidly if patient tolerates well 2

For long-term use (≥1 year):

• Use 10% per month or slower 1
• Tapers may require several months to years 1, 2
• Longer opioid exposure requires proportionally longer tapers 1

Patient-Centered Collaborative Approach

Essential Patient Involvement

• Collaborate with the patient on the specific tapering plan, including the speed of reduction and when to pause 1
• Establish clear goals for continued therapy or discontinuation 1
• Patients often feel and function better after tapering, which should be communicated 2

Monitoring Frequency

• Follow up at least monthly during active tapering 1
• Utilize team members (nurses, pharmacists, behavioral health professionals) for telephone, telehealth, or face-to-face contact 1

Managing Withdrawal Symptoms

Recognition of Withdrawal

• Physical withdrawal manifests as restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, vomiting, diarrhea, increased blood pressure, respiratory rate, or heart rate 3
• Clinically significant withdrawal symptoms signal the need to slow the taper further 1

Pharmacological Adjuvants for Withdrawal

• α2-Agonists directly attenuate withdrawal: Clonidine (monitor for orthostasis/hypotension), tizanidine (less effective but safer), or lofexidine (FDA-approved for opioid withdrawal) 2
• For anxiety, insomnia, irritability: Trazodone, tricyclic antidepressants, gabapentin, or mirtazapine for short-term use 2
• For gastrointestinal symptoms: Loperamide (caution: can be abused in high doses) 2

Protracted Withdrawal Syndrome

• Months after opioid elimination, patients may experience dysphoria, irritability, insomnia, anhedonia, or vague malaise 2
• These symptoms must be anticipated, discussed, and treated 2
• Cannot be easily differentiated from underlying chronic pain conditions 2

Practical Tapering Strategies

Flexible Taper Adjustments

• Tapers may need to be paused and restarted when the patient is ready 1
• Slow the taper as patients reach lower dosages 1
• For patients struggling to tolerate tapering, maximize nonopioid pain treatments and address behavioral distress 1

Final Discontinuation Technique

• After reaching the smallest available dose, extend the interval between doses 1
• Discontinue when dosing frequency is less than once daily 1

Conversion Considerations

• Avoid converting to methadone for outpatient tapering due to complex pharmacokinetics, nonlinear morphine equivalency, multiple drug interactions, and high lethality risk, unless clinician has specific expertise 2

Critical Safety Measures

Overdose Risk After Tapering

• Advise patients of increased overdose risk if returning to previously prescribed higher doses due to loss of opioid tolerance 1
• Provide opioid overdose education and offer naloxone 1

Screen for Comorbidities

• Remain alert for anxiety, depression, and opioid use disorder that may be revealed during tapering 1
• Provide treatment or arrange management of these conditions 1

Special Populations

• Pregnancy: Access appropriate expertise before tapering due to risks to both patient and fetus from withdrawal 1
• Elderly: Start with lower doses and taper more cautiously due to increased sensitivity to respiratory depression 3
• Hepatic impairment: Use lower starting doses and slower tapers due to decreased clearance 3
• Renal impairment: Use lower doses and slower tapers as metabolites accumulate 3

Maximize Nonopioid Treatments

• Implement nonpharmacologic treatments (cognitive behavioral therapy, mindfulness, relaxation training, physical/occupational therapy, graded exercise) 1, 2
• Optimize nonopioid pharmacologic treatments throughout the taper 1